[go: up one dir, main page]

NO20073254L - Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for a behandle hepatisk encefalopati - Google Patents

Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for a behandle hepatisk encefalopati

Info

Publication number
NO20073254L
NO20073254L NO20073254A NO20073254A NO20073254L NO 20073254 L NO20073254 L NO 20073254L NO 20073254 A NO20073254 A NO 20073254A NO 20073254 A NO20073254 A NO 20073254A NO 20073254 L NO20073254 L NO 20073254L
Authority
NO
Norway
Prior art keywords
phenylbutyrate
phenylacetate
ornithine
compositions
hepatic encephalopathy
Prior art date
Application number
NO20073254A
Other languages
English (en)
Other versions
NO342198B1 (no
Inventor
Rajiv Jalan
Kamal Nayan Jalan
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0426141A external-priority patent/GB0426141D0/en
Priority claimed from GB0426142A external-priority patent/GB0426142D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of NO20073254L publication Critical patent/NO20073254L/no
Publication of NO342198B1 publication Critical patent/NO342198B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelse av ornitin i fremstilling av et medikament for anvendelse i kombinasjon med minst en av fenylacetat og fenylbutyrat for å forebygge eller behandle leverdekompensasjon eller hepatisk encefalopati. Oppfinnelsen vedrører også anvendelse av minst en av fenylacetat og fenylbutyrat i fremstilling av et medikament for anvendelse i kombinasjon med ornitin for å forebygge eller behandle leverdekompensasjon eller hepatisk encefalopati.
NO20073254A 2004-11-26 2007-06-25 Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for å behandle hepatisk encefalopati NO342198B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0426141A GB0426141D0 (en) 2004-11-26 2004-11-26 Treatment
GB0426142A GB0426142D0 (en) 2004-11-26 2004-11-26 Formulation
PCT/GB2005/004539 WO2006056794A1 (en) 2004-11-26 2005-11-28 Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy

Publications (2)

Publication Number Publication Date
NO20073254L true NO20073254L (no) 2007-08-23
NO342198B1 NO342198B1 (no) 2018-04-16

Family

ID=35559327

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20073254A NO342198B1 (no) 2004-11-26 2007-06-25 Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for å behandle hepatisk encefalopati
NO20161808A NO341491B1 (no) 2004-11-26 2016-11-16 Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for å behandle hepatisk encefalopati

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20161808A NO341491B1 (no) 2004-11-26 2016-11-16 Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for å behandle hepatisk encefalopati

Country Status (22)

Country Link
US (3) US8389576B2 (no)
EP (3) EP2319581B1 (no)
JP (2) JP5116479B2 (no)
KR (1) KR101380446B1 (no)
CN (1) CN102512408B (no)
AT (1) ATE457187T1 (no)
AU (1) AU2005308622B2 (no)
CA (1) CA2589261C (no)
CY (3) CY1112259T1 (no)
DE (1) DE602005019319D1 (no)
DK (3) DK1824563T3 (no)
EA (2) EA018007B1 (no)
ES (3) ES2341120T3 (no)
IL (1) IL183401A (no)
MX (1) MX2007006171A (no)
NO (2) NO342198B1 (no)
NZ (1) NZ555870A (no)
PL (3) PL2153870T3 (no)
PT (3) PT2153870E (no)
SG (1) SG158073A1 (no)
SI (3) SI2319581T1 (no)
WO (1) WO2006056794A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018007B1 (ru) 2004-11-26 2013-04-30 Ю Си Эл БИЗНЕС Пи Эл Си Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
GB2465250B (en) * 2008-08-29 2011-01-26 Ucyclyd Pharma Inc Dosing and monitoring patients on nitrogen-scavenging drugs
WO2009134460A1 (en) * 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
AU2009298389C1 (en) 2008-10-02 2016-04-28 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
KR101975726B1 (ko) 2009-04-03 2019-05-07 오세라 테라퓨틱스, 아이엔씨. Ｌ-오르니틴 페닐 아세테이트, 및 이의 제조방법
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
EP2397458A1 (en) * 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
CN103502203B (zh) 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法
AU2012316750B2 (en) * 2011-09-30 2017-08-31 Immedica Pharma Ab Methods of therapeutic monitoring of nitrogen scavenging drugs
AU2012377389A1 (en) 2012-04-20 2014-10-30 Horizon Therapeutics Llc Methods of therapeutic monitoring of phenylacetic acid prodrugs
PL2922576T3 (pl) 2012-11-21 2018-08-31 Horizon Therapeutics, Llc Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
EP3019074B1 (en) * 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
EP3099306B1 (en) 2014-01-29 2018-12-12 Umecrine Cognition AB Steroid compound for use in the treatment of hepatic encephalopathy
EP3685841A1 (en) * 2014-11-24 2020-07-29 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
EP3285756B1 (en) * 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
CA2995823A1 (en) * 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
HK1257679A1 (zh) * 2015-09-25 2019-10-25 Ocera Therapeutics, Inc. 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
MX389926B (es) * 2015-11-13 2025-03-20 Ocera Therapeutics Inc Formulaciones de fenilacetato de l-ornitina
WO2017090007A1 (en) * 2015-11-29 2017-06-01 Rao M Surya Compositions and methods for the treatment of urea cycle disorders and hepatic diseases
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018208677A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
WO2018225167A1 (ja) 2017-06-07 2018-12-13 花王株式会社 アンモニア代謝促進剤
WO2018225482A1 (ja) 2017-06-07 2018-12-13 花王株式会社 アンモニア代謝促進剤
JOP20200033A1 (ar) 2017-08-14 2020-02-13 Axcella Health Inc تركيبات حمض أميني لمعالجة مرض كبدي
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
WO2019246225A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP7197340B2 (ja) * 2018-12-06 2022-12-27 花王株式会社 認知機能改善剤
JP2022533569A (ja) 2019-05-09 2022-07-25 オセラ セラピューティクス， インコーポレイテッド 肝性脳症を評価および処置する方法
CN113713817B (zh) * 2020-05-26 2023-06-27 中国科学院大连化学物理研究所 一种采用镍基催化剂催化丙醛加氢制正丙醇的方法
CN116782912A (zh) * 2020-12-01 2023-09-19 维尔斯达医疗公司 5'-o-苯乙酰基尿苷及其治疗用途
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate
WO2025137400A1 (en) * 2023-12-20 2025-06-26 Cedars-Sinai Medical Center Use of tenapanor for the treatment or prevention of hepatic encephalopathy

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE380814A (no) * 1930-06-26
US1980422A (en) * 1931-09-30 1934-11-13 Mesick John Plotting board
US2271378A (en) * 1939-08-30 1942-01-27 Du Pont Pest control
US2273780A (en) * 1939-12-30 1942-02-17 Du Pont Wax acryalte ester blends
US2261002A (en) * 1941-06-17 1941-10-28 Du Pont Organic nitrogen compounds
US2388614A (en) * 1942-05-05 1945-11-06 Du Pont Disinfectant compositions
US2375853A (en) * 1942-10-07 1945-05-15 Du Pont Diamine derivatives
US2454547A (en) * 1946-10-15 1948-11-23 Rohm & Haas Polymeric quaternary ammonium salts
US2723248A (en) * 1954-10-01 1955-11-08 Gen Aniline & Film Corp Film-forming compositions
US2961347A (en) * 1957-11-13 1960-11-22 Hercules Powder Co Ltd Process for preventing shrinkage and felting of wool
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
US3227615A (en) * 1962-05-29 1966-01-04 Hercules Powder Co Ltd Process and composition for the permanent waving of hair
US3206462A (en) * 1962-10-31 1965-09-14 Dow Chemical Co Quaternary poly(oxyalkylene)alkylbis(diethylenetriamine) compounds
NL302572A (no) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
US3256154A (en) * 1963-10-18 1966-06-14 Gillette Co Hair waving composition and method
FR1517743A (fr) * 1966-08-03 1968-03-22 Oreal Nouveaux copolymères et compositions cosmétiques contenant ces copolymères
US3472840A (en) * 1965-09-14 1969-10-14 Union Carbide Corp Quaternary nitrogen-containing cellulose ethers
US3810977A (en) * 1967-03-23 1974-05-14 Nat Starch Chem Corp Hair fixing composition and process containing a solid terpolymer
CH491153A (de) * 1967-09-28 1970-05-31 Sandoz Ag Verfahren zur Herstellung von neuen kationaktiven, wasserlöslichen Polyamiden
US3836537A (en) * 1970-10-07 1974-09-17 Minnesota Mining & Mfg Zwitterionic polymer hairsetting compositions and method of using same
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4013787A (en) * 1971-11-29 1977-03-22 Societe Anonyme Dite: L'oreal Piperazine based polymer and hair treating composition containing the same
LU64371A1 (no) * 1971-11-29 1973-06-21
LU65552A1 (no) * 1972-06-20 1973-12-27
CA981746A (en) * 1973-09-24 1976-01-13 Alfred M. Hase Battery charging circuit
US4189468A (en) * 1973-11-30 1980-02-19 L'oreal Crosslinked polyamino-polyamide in hair conditioning compositions
US4277581A (en) * 1973-11-30 1981-07-07 L'oreal Polyamino-polyamide crosslinked with crosslinking agent
US4172887A (en) * 1973-11-30 1979-10-30 L'oreal Hair conditioning compositions containing crosslinked polyaminopolyamides
US3874870A (en) * 1973-12-18 1975-04-01 Mill Master Onyx Corp Microbiocidal polymeric quarternary ammonium compounds
US3929990A (en) * 1973-12-18 1975-12-30 Millmaster Onyx Corp Microbiocidal polymeric quaternary ammonium compounds
US4025627A (en) * 1973-12-18 1977-05-24 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
DK659674A (no) * 1974-01-25 1975-09-29 Calgon Corp
US4166894A (en) * 1974-01-25 1979-09-04 Calgon Corporation Functional ionene compositions and their use
LU69760A1 (no) * 1974-04-01 1976-03-17
LU69759A1 (no) * 1974-04-01 1976-03-17
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US4948579A (en) * 1974-05-16 1990-08-14 Societe Anonyme Dite: L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4217914A (en) * 1974-05-16 1980-08-19 L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4422853A (en) * 1974-05-16 1983-12-27 L'oreal Hair dyeing compositions containing quaternized polymer
US5196189A (en) * 1974-05-16 1993-03-23 Societe Anonyme Dite: L'oreal Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin
US4005193A (en) * 1974-08-07 1977-01-25 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US4026945A (en) * 1974-10-03 1977-05-31 Millmaster Onyx Corporation Anti-microbial quaternary ammonium co-polymers
US4025617A (en) * 1974-10-03 1977-05-24 Millmaster Onyx Corporation Anti-microbial quaternary ammonium co-polymers
US3966904A (en) * 1974-10-03 1976-06-29 Millmaster Onyx Corporation Quaternary ammonium co-polymers for controlling the proliferation of bacteria
US4001432A (en) * 1974-10-29 1977-01-04 Millmaster Onyx Corporation Method of inhibiting the growth of bacteria by the application thereto of capped polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4025653A (en) * 1975-04-07 1977-05-24 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US4197865A (en) * 1975-07-04 1980-04-15 L'oreal Treating hair with quaternized polymers
AT365448B (de) * 1975-07-04 1982-01-11 Oreal Kosmetische zubereitung
IT1082729B (it) * 1976-04-06 1985-05-21 Oreal Copolimeri acrilici e composizioni cosmetiche contenenti tali copolimeri
US4031307A (en) * 1976-05-03 1977-06-21 Celanese Corporation Cationic polygalactomannan compositions
GB1572837A (en) * 1976-05-06 1980-08-06 Berger Jenson & Nicholson Ltd Coating composition
US4128631A (en) * 1977-02-16 1978-12-05 General Mills Chemicals, Inc. Method of imparting lubricity to keratinous substrates and mucous membranes
LU78153A1 (fr) * 1977-09-20 1979-05-25 Oreal Compositions cosmetiques a base de polymeres polyammonium quaternaires et procede de preparation
US4131576A (en) * 1977-12-15 1978-12-26 National Starch And Chemical Corporation Process for the preparation of graft copolymers of a water soluble monomer and polysaccharide employing a two-phase reaction system
US4228099A (en) * 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) * 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4970066A (en) * 1978-06-15 1990-11-13 L'oreal Hair dye or bleach supports of quaternized polymers
US4348202A (en) * 1978-06-15 1982-09-07 L'oreal Hair dye or bleach supports
FR2439798A1 (fr) * 1978-10-27 1980-05-23 Oreal Nouveaux copolymeres utilisables en cosmetique, notamment dans des laques et lotions de mises en plis
US4352814A (en) * 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
LU83349A1 (fr) * 1981-05-08 1983-03-24 Oreal Composition sous forme de mousse aerosol a base de polymere cationique et de polymere anionique
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
LU84463A1 (fr) * 1982-11-10 1984-06-13 Oreal Polymeres polysiloxanes polyquaternaires
LU84708A1 (fr) * 1983-03-23 1984-11-14 Oreal Composition epaissie ou gelifiee de conditionnement des cheveux contenant au moins un polymere cationique,au moins un polymere anionique et au moins une gomme de xanthane
US4812307A (en) * 1983-07-06 1989-03-14 Chesebrough-Pond's Inc. Crosslinking of hair thiols using glutathione disulfide
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP0269107A3 (en) * 1986-11-28 1989-10-11 Kao Corporation Composition for hair treatment agent
US4749732A (en) * 1987-01-02 1988-06-07 Dow Corning Corporation Hair care composition containing modified aminoalkyl substituted polydiorganosiloxane
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
US4795629A (en) * 1987-07-06 1989-01-03 Chesebrough-Pond's Inc. Crosslinking of hair thiols using cystamine
LU87310A1 (fr) * 1988-08-04 1990-03-13 Oreal N-(mercaptoalkyl)omega-hydroxyalkylamides et leur utilisation en tant qu'agents reducteurs,dans un procede de deformation permanente des cheveux
FR2654617B1 (fr) * 1989-11-20 1993-10-08 Oreal Composition cosmetique reductrice pour permanente contenant, en tant qu'agent reducteur, de l'aletheine ou l'un de ses sels, et son utilisation dans un procede de deformation permanente des cheveux.
DE4020980C1 (no) * 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) * 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
FR2676441B1 (fr) * 1991-05-17 1994-10-28 Oreal Nouveaux alkylamino-mercaptoalkylamides ou l'un de leurs sels cosmetiquement acceptables, et leur utilisation en tant qu'agents reducteurs, dans un procede de deformation permanente des cheveux.
FR2677543B1 (fr) * 1991-06-13 1993-09-24 Oreal Composition cosmetique filtrante a base d'acide benzene 1,4-di(3-methylidene-10-camphosulfonique) et de nanopigments d'oxydes metalliques.
US5767086A (en) * 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
EP1179347A4 (en) 1999-05-21 2002-06-26 Takeda Chemical Industries Ltd CONTROL SUBSTANCES FOR LIVER FUNCTION
US6768024B1 (en) * 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
TWI309162B (en) 2001-03-15 2009-05-01 Rikagaku Kenkyusho Amino acid composition for improving functional disorder of liver
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) * 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7589235B2 (en) 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
JP2008511611A (ja) 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
EA018007B1 (ru) 2004-11-26 2013-04-30 Ю Си Эл БИЗНЕС Пи Эл Си Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
GB0426141D0 (en) 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
JP5221858B2 (ja) 2006-08-30 2013-06-26 株式会社日立ハイテクノロジーズ 欠陥検査装置、及び欠陥検査方法
KR101975726B1 (ko) 2009-04-03 2019-05-07 오세라 테라퓨틱스, 아이엔씨. Ｌ-오르니틴 페닐 아세테이트, 및 이의 제조방법
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
CN103502203B (zh) 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法
EP3285756B1 (en) 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
HK1141471A1 (en) 2010-11-12
NO20161808A1 (no) 2016-11-16
JP2012246294A (ja) 2012-12-13
SG158073A1 (en) 2010-01-29
EP1824563A1 (en) 2007-08-29
US20120259016A1 (en) 2012-10-11
JP5116479B2 (ja) 2013-01-09
KR20070100721A (ko) 2007-10-11
NO341491B1 (no) 2017-11-27
EP2153870A1 (en) 2010-02-17
EP2319581A1 (en) 2011-05-11
CA2589261C (en) 2014-07-08
EP2319581B1 (en) 2015-02-25
NO342198B1 (no) 2018-04-16
PL2319581T3 (pl) 2015-10-30
MX2007006171A (es) 2007-10-08
AU2005308622B2 (en) 2012-08-02
EA200900105A1 (ru) 2009-08-28
DE602005019319D1 (de) 2010-03-25
ATE457187T1 (de) 2010-02-15
CY1112259T1 (el) 2015-12-09
US20170189364A1 (en) 2017-07-06
US20080119554A1 (en) 2008-05-22
CY1114979T1 (el) 2016-12-14
CN102512408B (zh) 2015-11-25
US10610506B2 (en) 2020-04-07
PL2153870T3 (pl) 2014-05-30
PT2319581E (pt) 2015-06-30
JP5612030B2 (ja) 2014-10-22
DK1824563T3 (da) 2010-05-31
DK2319581T3 (en) 2015-06-01
KR101380446B1 (ko) 2014-04-01
AU2005308622A1 (en) 2006-06-01
ES2537974T3 (es) 2015-06-16
PL1824563T3 (pl) 2010-07-30
CA2589261A1 (en) 2006-06-01
EA018007B1 (ru) 2013-04-30
NZ555870A (en) 2009-09-25
CY1116314T1 (el) 2017-02-08
ES2341120T3 (es) 2010-06-15
JP2008521784A (ja) 2008-06-26
WO2006056794A1 (en) 2006-06-01
EP1824563B1 (en) 2010-02-10
PT2153870E (pt) 2014-03-12
IL183401A (en) 2013-09-30
EA200701146A1 (ru) 2008-02-28
IL183401A0 (en) 2007-10-31
SI1824563T1 (sl) 2010-07-30
US8389576B2 (en) 2013-03-05
EP2153870B1 (en) 2013-12-25
ES2448549T3 (es) 2014-03-14
CN102512408A (zh) 2012-06-27
EA011716B1 (ru) 2009-04-28
PT1824563E (pt) 2010-05-17
DK2153870T3 (en) 2014-03-10
US9566257B2 (en) 2017-02-14
SI2319581T1 (sl) 2015-10-30
SI2153870T1 (sl) 2014-05-30

Similar Documents

Publication Publication Date Title
NO20073254L (no) Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for a behandle hepatisk encefalopati
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
ECSP10010002A (es) Derivados indólicos 2,3 sustituidos y métodos de uso de los mismos
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CY1116931T1 (el) Στοματικο σκευασμα μεταδοξινης
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
NO20076405L (no) Anvendelse av 24-nor-UDCA
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
MX2009011900A (es) Curacion de herida diabetica.
IT1398773B1 (it) Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico.
BR112012028153A2 (pt) composição farmacêutica e método para o tratamento de hipertensão
TNSN07364A1 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
ZA200704950B (en) Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalpathy
HRP20050580B1 (hr) Sinergistiäśki uäśinak kombinacije roflumilasta i (r,r)-formoterola
TW200615000A (en) Use of arginase for the treatment of hepatitis
CY1115890T1 (el) Εισπνεομενες φαρμακοτεχνικες μορφες διπλης δρασης παρεχοντας αμφοτερα ενα προφιλ αμεσης και κατακρατημενης αποδεσμευσης
CN105940777C (zh) 种抗病毒的中药组合物